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Abstract
Background: As antimicrobials increase the risk of acquiring multidrug-resistant (MDR) bacteria, unnecessary
antibiotics should be avoided for travellers’ diarrhoea (TD). Antibiotics are recommended in TD accompanied by
fever or incapacitation (TD justifying use of antibiotics, TDjuAB). Seeking tools for reducing antibiotic use, we
explored factors predisposing to TDjuAB and scrutinized antibiotic treatment among those with TDjuAB [TDjuAB(+)
subgroup] and those with diarrhoea not justifying antibiotics [TDjuAB(−) subgroup].
Methods: We conducted a study among 370 prospectively recruited visitors to the tropics. Stool samples and ques-
tionnaires were collected before and after travel. Enteric pathogens were analysed by qPCR for enteropathogenic
(EPEC), enteroaggregative (EAEC), enterotoxigenic (ETEC), enterohaemorrhagic (EHEC) and enteroinvasive (EIEC)
E. coli/Shigella, Campylobacter , Salmonella, Yersinia and Vibrio cholerae, and for ETEC’s toxins LT (heat-labile),
STh (human heat-stable) and STp (porcine heat-stable). TD was defined by the WHO criteria and TDjuAB as
diarrhoea accompanied by fever, and/or disrupting or preventing daily activities. Multivariable analysis was
applied—separately for travel-related factors and pathogens—to identify risk factors for TDjuAB(+).
Results: Among the 370 travellers, TD was contracted by 253 (68%), categorized as TDjuAB(+) in 93/253 (37%)
and TDjuAB(−) in 160/253 (63%) of the cases. Antibiotics were used for TD by 41% in TDjuAB(+) and by 7% in
the TDjuAB(−) group. Relative risk ratios (RRR)s are presented for both the TDjuAB(+) and the TDjuAB(−) groups.
TDjuAB(+) was associated with long travel duration and young age. Among the 298 subjects not having taken
antibiotics, increased RRRs were found e.g. for findings of Campylobacter coli/jejuni and ETEC’s STh toxin.
Conclusions: The first to analyse risk factors for TDjuAB, our study presents RRRs for demographic and behavioural
factors and for various pathogens. Only less than half of those in the TDjuAB(+) group took antibiotics, which
demonstrates that most cases meeting the current criteria recover without antimicrobial treatment.
Key words: Antibiotic treatment, antimicrobial resistance, multidrug-resistant bacteria, severe travellers’ diarrhoea, MDR, TD guidelines,
international travel
Introduction
Visitors to emerging economies stay in conditions with weak
hygiene infrastructure. Their most common health problem
is travellers’ diarrhoea (TD). with attack rates varying by
destination between 30 and 70%.1–3 Previously, antibiotics were
the mainstay of TD treatment,4 but ever since their use was
shown to predispose to acquisition of multidrug-resistant (MDR)
bacteria,5–9 less liberal antibiotic practices have been rec-
ommended. With colonization rates up to 20–70%,10 ,11
international travellers act as transporters of MDR bacteria,
contributing to the spread of antimicrobial resistance (AMR)
worldwide.11 ,12
To prevent MDR acquisition, pre-travel advice should
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Figure 1. Flow chart of study conduct
weak hygiene infrastructures,5–7 ,9 ,13–17 contracting TD5–9 ,13 ,14
and use of antimicrobials.5–9 ,16 Although travel destination is
generally set before seeking pre-travel advice, special attention
should be paid to TD prevention and avoidance of unnecessary
antibiotics.
Prevention of TD appears to be an ineffective approach: there
are no broadly effective vaccines against TD and, as numerous
studies report, food, drink and hygiene precautions have only
limited or negligible preventive effect.18–28 Indeed, for the time
being, restricting antibiotic use appears to be the only realistic
means available of reducing the rate of MDR bacteria acqui-
sition. An obvious focus is TD treatment abroad, since up to
86% of all antibiotics are taken there for TD.29 ,30 It should be
emphasized, however, that for patients with high fever or in poor
clinical condition, antibiotics are often warranted.31
The current national/international guidelines recommend to
consider antibiotics for healthy travellers who have TD with
fever or incapacitation31 or those with TD interfering with
planned activities.3 ,32 In a prospective study setting, seeking
tools to reduce antibiotic use, we (1) evaluated RRRs of poten-
tially predisposing travel-related factors as well as various TD
pathogens with respect to the outcome as TD with symptoms
justifying the use of antibiotics, TDjuAB(+), and (2) explored
whether all TD cases in this group require antibiotics. We are
not aware of any previous studies with this focus.
Materials and methods
Study design and subjects
Travellers were recruited prospectively at the Aava Travel Clinic,
Helsinki in 2008–10 and asked to fill in pre-travel Q1 (demo-
graphics, itinerary) and post-travel Q2 questionnaires (travel-
related items, symptoms, antibiotic use) and a health diary
(daily TD symptoms, specifics on antibiotic use) while abroad
(Figure 1), and provide pre- and post-travel stool samples; for
details of the study protocol, see our previous report.6
Definitions
TD was defined by the WHO criteria as passage of three or
more loose or liquid stools per day, or more frequently than is
normal for the individual.33 TDjuAB was defined as diarrhoea
accompanied by fever and/or diarrhoeal disease which disrupts
or prevents daily activities [TDjuAB(+) subgroup]. All other
types of TD were categorized into the subgroup not justifying
antibiotic treatment, TDjuAB(−).
The destinations were recorded into one of six geographic
regions as modified from the UN definition (see Table 1).34 Those
visiting more than one region were ranked by the highest risk of
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Table 1. Study among 370 prospectively recruited travellers: univariable and multivariable analyses of demographic factors correlating
with the groups TDjuAB(+), TDjuAB(−) and no TD. Multivariable relative risk ratios (RRRs) are for TDjuAB(+) compared to no TD and for













Total, proportions of allc 93/370 (25) 160/370 (43) 117/370 (32)
Genderc 0.189
Male 37 (26) 54 (38) 52 (36)
Female 56 (25) 106 (47) 65 (29)
Age, median (IQR)cd 31 (26–43) 35 (27–55) 49 (30–60) <0.001 0.98 (0.96–1.00)e 0.99 (0.98–1.01)e
0–17 7/25 (28) 8/25 (32) 10/25 (40)
18–29 34/97 (35) 46/97 (47) 17/97 (18)
30–54 44/155 (28) 66/155 (43) 45/155 (29)
55–64 4/59 (7) 29/59 (49) 26/59 (44)
65– 4/34 (12) 11/34 (32) 19/34 (56)
Travel duration, median
(IQR)cd
25 (15–47) 17 (14–27) 15 (12–19) <0.001 1.03 (1.01–1.05)f 1.01 (0.99–1.03)f
4–7 days 2/7 (29) 2/7 (29) 3/7 (43)
8–29 days 53/284 (19) 130/284 (46) 101/284 (36)
30–160 days 38/79 (48) 28/79 (35) 13/79 (16)
Geographic regionc <0.001
South-Eastern Asia 37/97 (38) 36/97 (37) 24/97 (25) 3.7 (0.8–18.3) 3.0 (0.8–11.6)
Eastern Africa 15/87 (17) 48/87 (55) 24/87 (28) 2.0 (0.4–10.1) 4.5 (1.2–16.8)
Western Africa, Middle
Africa
15/73 (21) 30/73 (41) 28/73 (38) 2.3 (0.4–12.3) 3.2 (0.8–12.4)
Southern Asia 18/59 (31) 29/59 (49) 12/59 (20) 3.8 (0.7–20.4) 5.5 (1.4–22.2)
Latin America and the
Caribbean
5/35 (14) 12/35 (34) 18/35 (51) 1.2 (0.2–7.4) 1.9 (0.5–8.0)
Southern Africa 3/19 (16) 5/19 (26) 11/19 (58) 1.0 1.0
Abbreviations: travellers’ diarrhoea, TD; travellers’ diarrhoea justifying use of antibiotics, TDjuAB(+); travellers’ diarrhoea not justifying antibiotic treatment, TDjuAB(−); no travellers’
diarrhoea, no TD
aTD was defined by WHO diarrhoea criteria (passage of ≥3 loose or liquid stools per day, or more frequently than normal for the individual
bFactor with P-value under 0.20 in univariable analyses were chosen to the multivariable model. Multinomial logistic regression was used with multiple imputations (70 data sets).
The model included gender, age (continuous), geographic region, travel duration (continuous), location, accommodation, diet, use of utensils, freshwater contact, insect stings, alcohol
consumption and hypertension (for hypertension univariable P-value 0.075).
cmissing data 0; danalysed as continuous variable; eper year; fper day
Risk factor analyses of TDjuAB(+)
Seeking tools to avoid TDjuAB, we conducted one multivariable
analysis focusing on RRRs for demographic and behavioural
patterns and for various pathogen findings associated with
TDjuAB(+). To allow simultaneous evaluation of the risk of
contracting any TD, we also presented the respective RRRs in
the TDjuAB(−) group.
As for hygienic precautions, we created a variable describ-
ing adherence to hygiene instructions and explored its asso-
ciation with TDjuAB(+). Compliance was evaluated by enu-
merating the general hygiene instructions that were followed
(from among drinking bottled water, handwashing, avoiding
salads, using utensils and eating cooked meat/fish). Those with
unanswered questions were excluded from analyses. The rate of
TDjuAB(+) was analysed between those having followed 1–3 vs
4–5 instructions.
Stool samples
DNA was isolated on arrival at the laboratory by the semi-
automated protocol of easyMAG (bioMérieux, Marcy-l’Etoile,
France) and stored at −80◦C. The stool pathogens were
examined by the previously described qPCR method.36 It covers
five diarrhoeagenic Escherichia coli including enteroaggregative
(EAEC), enteropathogenic (EPEC), enterotoxigenic (ETEC),
enterohaemorrhagic (EHEC), enteroinvasive (EIEC) E. coli
or Shigella, and Salmonella, Yersinia, Vibrio cholerae, and
Campylobacter coli/jejuni. Samples with ETEC were subjected
to PCR analysis of ST and LT toxins as depicted recently.37
Analyses of risk associated
with various pathogens
To exclude the confounding impact of the drugs, only travellers
not having used antibiotics were taken into our analyses of
pathogen-associated risks by comparing the TDjuAB(+) and
the TDjuAB(−) each with the no TD group. As an exception,
doxycycline as antimalarial was included, since, as continuous
medication, it was not expected to cause abrupt changes in the
microbiota abroad.
Statistical analysis
For univariable analyses we used Pearson chi-square plus
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Figure 2. Proportions of travellers with and without antibiotic use for TD in the TDjuAB(+) and TDjuAB(−) groups
logistic regression model. Statistical significance was set to a
P-value <0.05. Multivariable models were run for factors
correlating with TD variable (TDjuAB(+)/TDjuAB(−)/no
TD) with a P-value < 0.20 in univariable analysis. Multiple
imputations were conducted to have 70 data sets in multivariable
model of behavioural risk factors of TDjuAB(+) and TDjuAB(−),
and missing values were assumed to be missing at random
(MAR). Bayes’ model was used in pathogen analysis and the
selection of final model was done by deviance information
criterion (DIC). Two Markov chains were used and the million
simulations did converge. In the final multivariable models
relative risk ratios (RRR) and 95% confidence intervals plus
95% credible intervals (Bayes) were calculated. SPSS Statistics
(version 25.0 64-bit, IBM Corp. in Armonk, NY) and Stata 16
(StataCorp, College Station, TX) were used in statistical analyses.
Results
Study population
As from among the 524 travellers recruited 154 were excluded,
the final study population comprised 370 participants (Figure 1),
all having provided post-travel stool samples (one of which was
discarded for improper handling). In analyses investigating RRRs
in the TDjuAB(+) and the TDjuAB(−) group with respect to each
pathogen, we included findings of those 298/370 (81%) who had
not used antibiotics (except doxycycline as malaria prophylaxis).
For demographics, see Supplementary Table S1.
Specifics of TDjuAB(+), TDjuAB(−)
and no TD groups
Of the final study population, TD was contracted by 253/370
(68%), categorized as TDjuAB(+) in 93 (37%) and TDjuAB(−)
in 160 (63%) cases. In the TDjuAB(+) group, the median
travel duration was 25 days and the median age 31 years,
in the TDjuAB(−) group 17 days and 35 years, and among
those with no TD 15 days and 49 years, respectively. There
were no gender differences between the groups (Supplementary
Table 1). TD was treated with antibiotics by 38/93 (41%)
in the TDjuAB(+) and 11/160 (7%) in the TDjuAB(−)
group (Figure 2).
Risk factors for TDjuAB(+)
Seeking tools to avoid TDjuAB, we explored the factors associ-
ated with TDjuAB(+). To provide data on the risk of milder TD,
we also show RRRs in the TDjuAB(−) group.
Univariable analysis of behavioural factors. In univariable analysis
comparing the TDjuAB(+), TDjuAB(−), and no TD groups,
TDjuAB(+) was associated with age, duration of travel, geo-
graphic region (Table 1), type of accommodation, freshwater
contact, insect stings, use of probiotics, and healthcare visit
(Table 2).
Over half (60%) of all participants complied with four to five
hygiene instructions; hardly any differences were seen between
the three subgroups: 52% in the group TDjuAB(+), 62% in
TDjuAB(−), and 61% in no TD (P = 0.287; Table 2).
Multivariable analysis of demographics and behavioural factors. For
multivariable analysis we selected factors that showed in uni-
variable analysis a P-value < 0.2 for correlation with TDjuAB
variable (Tables 1 and 2). Comparisons were made between the
groups TDjuAB(+) vs no TD and TDjuAB(−) vs no TD. As
factors with increased risk in the TDjuAB(+) group, we identified
longer travel duration (RRR/day 1.028; 95% 1.009–1.048) and
younger age (RRR/year 0.979; 95% 0.961–0.998). Vegetarian
diet may also be linked with TDjuAB(+) (RRR 3.2; 95% 0.85–
12) as well as Southern Asia (RRR 3.8; 95% 0.71–20) and South-
eastern Asia as destination (RRR 3.7; 95% 0.75–18; compared
to Southern Africa). Increased RRRs were also found in the
TDjuAB(−) group as shown in Tables 1 and 2.
Stool bacteria associated with TDjuAB(+). Among the travellers who
had not taken antibiotics, 50/298 (17%) belonged to the sub-
group TDjuAB(+), 138/298 (46%) to TDjuAB(−) and 110/298
(37%) to no TD. The stool findings were compared between non-
antibiotic users of TDjuAB(+) vs no TD and TDjuAB(−) vs no
TD groups.
In univariable analyses an increased RRR was found in the
TDjuAB(+) group for Campylobacter coli/jejuni (8/25; 32%;
P = 0.048) and ETEC’s toxin STh (STh; 6/11; 55%; P = 0.004)
(Table 3). All travellers with STh ETEC and all except one with
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Table 2. Univariable and multivariable model on behavioural factors correlating with the goups TDjuAB(+), TDjuAB(−) and no TD. RRRs
are for TDjuAB(+) compared to no TD and for TDjuAB(−) compared to no TD. The variables of multivariable analysis are presented in














City 22/102 (22) 41/102 (40) 39/102 (38)
Countryside/jungle 70/254 (28) 112/254 (44) 72/254 (28)
Accommodationc 0.002
Hotel 25/141 (18) 56/141 (40) 60/141 (43) 1.0 1.0
Home of a local 16/57 (28) 25/57 (44) 16/57 (28) 1.2 (0.5–3.4) 1.1 (0.5–2.6)
Guest house 52/165 (32) 76/165 (46) 37/165 (22) 1.6 (0.8–3.4) 1.6 (0.9–2.9)
Type of toiletc 0.469
WC as a toilet 75/303 (25) 128/303 (42) 100/303 (33)
Other type of toilet 16/60 (27) 29/60 (48) 15/60 (25)
Used other than bottled waterd 4/19 (21) 8/19 (42) 7/19 (37) 0.851
Alcohol consumptione 0.116
0–2 units per day 68/232 (29) 101/232 (44) 63/232 (27)
3– units per day 17/85 (20) 36/85 (42) 32/85 (38)
Site of mealsf 0.853
Restaurant >50% of meals 79/299 (26) 126/299 (42) 94/299 (31)
Mostly own household 14/61 (23) 27/61 (44) 20/61 (33)
Ate uncooked meat/fishd 14/47 (30) 14/47 (30) 19/47 (40) 0.127
Did not wash hands always/ofteng 12/49 (24) 21/49 (43) 16/49 (33) 0.978
Ate saladsh 68/271 (25) 122/271 (45) 81/271 (30) 0.567
Dieti 0.065
Omnivore 54/232 (23) 105/232 (45) 73/232 (31) 1.0 1.0
Vegetarian 10/25 (40) 12/25 (48) 3/25 (12) 3.2 (0.9–11.7) 1.9 (0.5–7.0)
Used milk as part of dieti 63/252 (25) 115/252 (46) 74/252 (29) 0.859
Did not always use utensilsj 37/107 (35) 44/107 (41) 26/107 (24) 0.029
Freshwater contactk 40/95 (42) 32/95 (34) 23/95 (24) <0.001
Walked barefoot often/sometimesl 74/267 (28) 111/267 (42) 82/267 (31) 0.283
Unprotected sex with localm 3/7 (43) 3/7 (43) 1/7 (14) 0.489
Other close contact with localm 21/67 (31) 29/67 (43) 17/67 (25) 0.369
Insect stingsn 21/67 (31) 29/67 (43) 17/67 (25) 0.024
Behavioural advice followedo 0.287
1–3 advice 41/138 (30) 55/138 (40) 42/138 (30)
4–5 advice 45/203 (22) 91/203 (45) 67/203 (33)
Probiotics/prebioticsp 0.007
No 25/138 (18) 56/138 (41) 57/138 (41)
Before and while travelling 41/121 (34) 52/121 (43) 28/121 (23)
While abroad 27/109 (25) 51/109 (47) 31/109 (28)
SBA carriedq 18/59 (31) 25/59 (42) 16/59 (27) 0.573
Healthcare visitr <0.001
No healthcare visit 65/326 (20) 152/326 (47) 109/326 (33)
Healthcare visit due to TD 21/22 (95) 1/22 (5) 0/22 (0)
Healthcare visit for other reason 7/22 (32) 7/22 (32) 8/22 (36)
Antibiotic user <0.001
No use of antibiotics 50/298 (17) 138/298 (46) 110/298 (37)
Antibiotic use for diarrhoea 38/49 (78) 11/49 (22) 0/49 (0)
Antibiotic use for other reason 5/23 (22) 11/23 (48) 7/23 (30)
Abbreviations: SBA, stand-by antibiotics
aFactor with P-value < 0.20 in univariable analyses were chosen to the multivariable model. Multinomial logistic regression was used with multiple imputations (70 data sets). The model
included gender, age (continuous), geographic region, travel duration (continuous), location, accommodation, diet, use of utensils, freshwater contact, insect stings, alcohol consumption and
hypertension (for hypertension univariable P-value 0.075).
bMissing data 14; cmissing data 7; dmissing data 3; emissing data 53; fmissing data 10; gmissing data 8; hmissing data 18; imissing data 113; jmissing data 15; kmissing data 126;
lmissing data 6; mmissing data 19; nmissing data 16; omissing data 29; pmissing data 2; qmissing data 69; rmissing data 0
Shigella/EIEC had TD, yet their number was low and statistical
significance was not reached.
In multivariable analysis, STh ETEC (RRR 15000, 95% CI
12–120 000), Campylobacter coli/jejuni (RRR 85, 95% CI 3.2–
460), and EAEC (RRR 2.3, 95% CI 1.02–4.6) were associ-
ated with TDjuAB(+) (Table 3). They were also associated with
TDjuAB(−), the RRRs provided in Table 3. It is noteworthy that
the RRR for EAEC was very similar in the TDjuAB(+) and the
TDjuAB(−) groups, whereas for the first two pathogens, there
appeared to be a difference. Priors for the parameters gender, age
and travel duration were non-informative. Behavioural factors
were added to the model, yet they were conditional to the
pathogens and no longer associated with the outcome, thus the
direct effect of behavioural factors did not predict the severity of
TD, whereas pathogens did.
Discussion
As antibiotic use is a major factor predisposing travellers to
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Table 3. Univariable and multivariable model on pathogen findings correlating with TDjuAB(+), TDjuAB(−), and no TD among 298 travellers













Total, proportions of all 50/298 (17) 138/298 (46) 110/298 (37)
Salmonellac 1/6 (17) 2/6 (33) 3/6 (50) 0.861
Campylobacterc 8/25(32) 16/25(64) 1/25 (4) 0.001 85 (3.2–460) 62 (2.8–340)
Shigella/EIECc 2/4 (50) 2/4 (50) 0/4 (0) 0.126
EAECc 25/136 (18) 74/136 (54) 37/136 (27) 0.007 2.3 (1.03–4.6) 2.4 (1.3–4.0)
EHECc 7/25 (28) 11/25 (44) 7/25 (28) 0.270
EPECc 22/148 (15) 71/148 (48) 55/148 (37) 0.656
ETECc 13/68 (19) 43/68 (63) 12/68 (18) 0.001
LTd 10/52 (19) 32/52 (62) 10/52 (19) 0.013 1.7 (0.49–4.5) 2.5 (1.04–5.5)
SThd 6/11 (55) 5/11 (45) 0/11 (0) 0.002 15 000
(12–120 000)
2500 (2.5–18 000)
STpd 4/19 (21) 12/19 (63) 3/19 (16) 0.144
Any pathogenc 41/233 (18) 117/233 (50) 75/233 (32) 0.008
Multiple pathogensc 26/130 (20) 71/130 (55) 33/130 (30) 0.002
aReference category no TD. Variables with P < 0.20 were chosen to the multivariable model: Campylobacter coli/jejuni, Shigella/EIEC, EAEC, LT, STh, STp, gender (priori), age
(continuous, standard deviation, priori) and travel duration (continuous, standard deviation, priori). Result for age RRR 0.67 (95% CI 0.44–0.96) and for travel duration RRR 1.9
(95% CI 1.05–3.2).
bReference category no TD. Variables with P < 0.20 were chosen to the multivariable model: Campylobacter coli/jejuni, Shigella/EIEC, EAEC, LT, STh, STp, gender (priori), age
(continuous, standard deviation, priori) and travel duration (continuous, standard deviation, priori). Result for age RRR 0.73 (95% CI 0.55–0.96) and for travel duration RRR 1.4
(95% CI 0.86–2.4)
cmissing data 1; dmissing data 4
the consumption. While abroad, antibiotics are mainly used for
TD.29 ,30 Therefore, so as to provide tools to reduce antibiotic
use for TD, we (i) conducted a multivariable analysis evaluating
the RRRs of potential factors predisposing to TDjuAB, and in
addition, (ii), to see if antibiotics are always needed in TDjuAB,
we explored whether part of travellers with TDjuAB actually
could manage without antibiotics. Not only did we evaluate the
RRRs for various factors potentially contributing to TDjuAB,




The recommendations concerning indications for antibiotic
use vary somewhat. As an example from North America,
the recommendation of the US Center for Disease control
and Prevention (CDC) advise that ‘Antibiotics should be used
to treat severe travelers’ diarrhea’. Severe TD is defined as
‘diarrhea that is incapacitating or completely prevents planned
activities; all dysentery ––.3 In Europe, the National Health
Service (NHS) Scotland recommends antibiotics to be considered
only for severe diarrhoea, ‘depending on the cause’. Severe
diarrhoea is defined as a disease with > 6 diarrhoea stools/24 h
which causes incapacitation, or there is blood/mucus in the
stools, or marked vomiting, fever, and/or stomach ache.31 An
expert panel supported by the International Society of Travel
Medicine (ISTM) states that antibiotics can be considered
for moderate TD and they should be used for severe TD,
which is defined as in CDC’s recommendation.32 TD justifying
use of antibiotics as used in the present study—denoting
incapacitating diarrhoeal disease and/or TD accompanied
with fever—was included both in the NHS listing when
to consider antibiotic treatment and the CDC and ISTM
recommendation for when antibiotics should be used for TD. The
present study yielded findings described below which favour the
former
recommendation.
Rate of TDjuAB(+) and antibiotic use
The TDjuAB(+) rate (37%) among our travellers with diarrhoea
accords with earlier studies. Among 784 US travellers, Hill
reports of 35% of those with TD having to alter their travel
plans.29 Similarly, Soonawala et al. found that 33% of Dutch
travellers with TD had to change their programme or were
confined to accommodation.38 Thus, these three studies suggest
that if all those with disabling disease would resort to antibiotics,
every third traveller with TD would use antibiotics, which
would imply for 2019—before Covid-19 outbreak—300 million
travellers with TD (600 million visitors to emerging economies39
with 50% TD frequency) around 100 million antibiotic
courses.
Our data clearly show that antibiotics are not necessary in
all cases of disabling diarrhoea: only 41% used the drugs for
TDjuAB. In other words, most of our participants with disabling
TD managed without antibiotics. Our results appear to accord
with those of Lalani et al., who report among 123 travellers with
moderate/severe TD an antibiotic consumption rate of 41%.40
However, their definition of moderate/severe TD covers acute
watery diarrhoea with decreased ability/complete inability to
participate in daily activities, whereas in our study the term
TDjuAB only refers to severe TD. Therefore, the results of these
two studies cannot be directly compared. Even considerably
lower antibiotic use rates for severe TD (10%) are reported by
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blood and/or mucus),41 the findings thus not quite comparable
with ours. However, as all these data show antibiotics not to be
needed in all cases of severe/incapacitating disease, the guidelines
stating that antibiotics can be considered31 appear more reason-
able than those recommending they should be used.32 It appears
justified that the guidelines be revised accordingly, i.e. to heed
this data calling for stricter, more prudent use of antibiotics.
In addition to data demonstrating that severe TD can often
be managed without antibiotics, more precise recommendations
are also grounded by studies questioning their actual benefits
in TD.42 Genton et al., by extrapolating the Cochrane data on
antibiotic treatment of TD43 into general traveller population,
conclude that three of six travellers with TD recover without
antibiotics within 72 h, whereas if all six were treated, four
will be cured, but at the cost of an adverse event to one trav-
eller.42 When antibiotics are taken, the median post-treatment
diarrhoea is 0.7–1.5 days shorter, and the number of unformed
stools per 24 h marginally lower (0–24 h − 1.6, 25–48 h − 2.1,
and 49–72 h − 1.4), yet with higher incidence (OR 2.4) of
adverse effects.43 They conclude that recommendations ‘rely on
low-quality evidence and are based on expert opinions or – even
worse – on commercial interest’.42
We only found one prospective investigation, a military
cohort study, looking at antibiotic treatment of moderate/severe
TD.40 It reports no difference between the antibiotic treatment
and non-treatment groups regarding time to last unformed stool
(TLUS) (P = 0.97), clinical cure at 24 h (P = 0.92), or clinical
cure at 48 h (P = 0.70). Rather, nausea was experienced by 30%
of travellers with moderate/severe TD using antibiotics plus
loperamide, compared to 0% of those only taking loperamide
(P = 0.005); for vomiting, the respective rates were 14% and 0%
(P = 0.15). The poor efficacy of antibiotics in severe TD may at
least partly be related to viral aetiology often linked to an excep-
tionally vigorous clinical picture.44–47 Clinical decision-making
frequently has to rely on clinical picture—in lack of aetiological
data, antimicrobials are warranted in the most severe cases.
It is not rare that travel medicine practitioners prescribe
stand-by antimicrobials (SBA) as a precaution for (severe) TD.
Unfortunately, however, prescription of SBA appears to lead to
overuse of antibiotics: we recently reported that those carrying
SBA resorted to them even in cases of mild/moderate diar-
rhoea, whereas those not carrying SBA mainly took antibiotics
for severe disease.48 As a recent development, the rate of SBA
prescriptions has decreased in the USA over the past decade.49
Behavioural risk factors for TDjuAB(+)
To get an overall picture of factors associated with any type
of TD, the RRRs of both the TDjuAB(+) and the TDjuAB(−)
group should be considered. However, as the present study is
primarily concerned with need for antibiotics as presumed in the
guidelines, the following discussion only looks at TDjuAB(+).
For those interested in TDjuAB(−), the Tables provide the
respective figures.
Multivariable analysis showed TDjuAB(+) to be associated
with long travel duration and younger age. Vegetarian diet
and Southern Asia plus South-eastern Asia as destinations also
appeared as risk factors, but did not reach statistical significance.
Although we found no previous studies exploring the risk factors
for TDjuAB(+), longer duration of travel and younger age have
been shown in several investigations to be risk factors for TD
in general.23 ,29 ,50–54 The association between TDjuAB(+) and
Southern Asia plus South-Eastern Asia may be linked to the
high TD risk in these destinations.29 ,38 ,54 Although our results
suggest vegetarian diet to be a risk factor of TDjuAB(+) (RRR
3.2; 95% CI 0.9–11.7; P = 0.085), we found no data in the
literature to support this. Such a finding might, however, be
explained by the relatively large proportion of uncooked food
in the vegetarian diet.
We found no strong correlation between behavioural factors
and TDjuAB(+). According with this, numerous studies search-
ing for tools to prevent TD have failed to prove the benefits
of hygienic and food/drink precautions.18–28 Mattila et al. found
no significant association between dietary errors and TD.21 In
the investigation by Cavalcanti et al. no single food or beverage
item could be linked to increased risk of diarrhoea.23 Hillel et al.,
report among long-term travellers that adherence to WHO’s pre-
cautions (avoiding unsafe food and drinks) did not correlate with
occurrence of diarrhoea.25 Likewise, in the study by Dia et al.
food hygiene did not prove efficient in preventing diarrhoea.27
Interestingly, the oral cholera vaccine Dukoral® has in some
countries as indication prevention of both cholera and TD: oral
B subunit—whole-cell cholera vaccine induces a cross-reactive
immune response to LT toxin of ETEC and has shown some
efficacy against ETEC TD in a field trial in Morocco.55 Further-
more, investigation into the composition of microbiota has been
suggested to provide tools for treatment and prevention of TD.56
Association between TDjuAB(+)
and various microbes
A possible association between the nine individual stool
pathogens or the three different ETEC (by toxin type) and
TDjuAB(+) was of special interest. Campylobacter coli/jejuni,
STh ETEC, and EAEC were found to be associated with
TDjuAB(+). However, the RRRs for EAEC were similar
in the TDjuAB(+) and the TDjuAB(−) group, whereas for
Campylobacter and STh ETEC, the RRRs appeared higher
in the TDjuAB(+) group. The link between STh ETEC and
TDjuAB(+) proved particularly strong: all of those with STh
had TD; TDjuAB(+) 55%, TDjuAB(−) 45%.
Our data accord with previous literature. Sanders et al. show
Campylobacter coli/jejuni to be associated with severe TD and
decreased functional ability among military personnel.57 Like-
wise, in Mattila’s investigation among tourists to Morocco, those
with diarrhoea caused by Campylobacter spp had the most
severe disease.58 In two paediatric studies STh ETEC proved
more pathogenic than STp ETEC59 ,60 and in one STh was the
most common toxin among hospitalized children with diar-
rhoea.61 Liu et al. investigating moderate to severe diarrhoea
among African and Asian children under 5 years found Shigella
spp, rotavirus, adenovirus 40/41, ST-ETEC, Cryptosporidium
spp, and Campylobacter spp to be the six major attributable
pathogens.62
We have earlier reported no association between pathogens
and severity of TD among travellers with symptoms ongoing at
return.63 Differing definitions may account for differing results:
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study categorized TD by number of stools.63 If judged by trav-
ellers’ antibiotic use for TD, the experience of severity appears to
be connected with incapacitation rather than number of stools.48
Limitations
Some limitations of the study deserve to be discussed. First, some
subgroup analyses were not powered enough to yield reliable
statistics (e.g. the low number of Shigella/EIEC cases). Second,
the same samples may have contained other pathogen findings
influencing the interpretation of association between pathogen
findings and TDjuAB(+). Indeed, analyses of bacterial pathogens
often showed multiple findings, whereas parasites and viruses
were not covered.
Conclusion
About one third of the travellers with diarrhoea had TD justi-
fying antibiotic treatment. Although the factors associated with
TDjuAB(+) (e.g. Campylobacter coli/jejuni and STh ETEC as
pathogens plus longer journey duration and younger age as
predisposing factors) may not offer any remarkable novel tools
for pre-travel counselling, the result that over half of those
with TDjuAB(+) managed without antibiotics bears consider-
able weight. In addition to indicating that the current catego-
rization of TDjuAB is invalid, these data show that treatment
guidelines should be revised and a stricter definition of cases
justifying antibiotic treatment should be introduced.
Supplementary data
Supplementary data are available at JTM online.
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ETEC enterotoxigenic Escherichia coli
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